US pharmaceutical market expected to be worth US$550bn by 2020, says GlobalData
New legislation is expected to have a direct or indirect impact on drug and biologic sales
The US pharmaceutical market is forecast to increase from an estimated US$395.2bn in 2014 to $548.4bn by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.6%, according to research and consulting firm GlobalData.
The company’s latest report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – The US, states that this growth will be driven by a number of factors, including increasing healthcare expenditure, an ageing population, the rising prevalence of chronic lifestyle diseases such as diabetes and obesity, universal and easy access to reimbursement for pharmaceutical product costs, and the 2010 Patient Protection and Affordable Care Act (PPACA).
Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says the PPACA and its amendment, the Health Care and Education Reconciliation Act, continue to have a substantial impact on US citizens and the country’s pharmaceutical industry.
New initiatives undertaken by the FDA to strengthen the review and approval process will be advantageous to the industry
He says: 'As the PPACA mandates health insurance coverage for all Americans, the US has witnessed increasing use of prescription drugs among individuals who are newly insured or have shifted to insurance plans that offer premium and cost-sharing subsidies. In 2014, spending on prescription drugs amounted to an estimated $275.9bn, compared with $262.3bn in 2013.
'Around 20 provisions of the healthcare legislation are expected to have a direct or indirect impact on the volume of drug and biologic sales. As many as 32 million formerly uninsured citizens could enter the patient pool, resulting in new business worth $115bn over a period of ten years.'
GlobalData also notes that the US Food and Drug Administration provides a transparent, well-structured and competent regulatory system to facilitate the approval of pharmaceutical products and consequently bolster market growth.
'New initiatives undertaken by the FDA to strengthen the review and approval process will be advantageous to the industry,' says Owide. 'Its strong patent system attracts research-based pharmaceutical companies and positively influences growth.'
In 2014, 41 novel drugs were approved by the FDA, 17 of which were for the treatment of rare diseases. Schemes such as the FDA’s Fast Track Development Programme and Breakthrough Designation accelerate the approval of novel drugs and add value to the market by meeting demand more quickly, says Owide.
